Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/5/2018
SIETES contiene 92334 citas

 
 
 1 a 20 de 135 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Campaigno EP, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-induced dental caries: a disproportionality analysis using data from VigiBase. Drug Saf 2017;40:1249-58. [Ref.ID 102146]
2. Cita con resumen
Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1-406. [Ref.ID 101044]
3. Cita con resumen
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AWS, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sulllivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MKB, STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77. [Ref.ID 100158]
4.Enlace a cita original Cita con resumen
Anónimo. Biphosphonates: very rare osteonecrosis of external ear canal . WHO Drug Information 2016;30:48. [Ref.ID 100125]
5.Enlace a cita original Cita con resumen
Anónimo. Prevención de fracturas osteoporóticas y duración del tratamiento. Boletín Terapéutico Andaluz 2015;30:1. [Ref.ID 99827]
6.Tiene citas relacionadas Cita con resumen
Brufsky A, Mathew A. Bisphosphonates, bone, and breast cancer recurrence. Lancet 2015;386:1319-20. [Ref.ID 99582]
7. Cita con resumen
Anónimo. Consolidations de fracture retardées par des médicaments. Prescrire 2015;35:507-12. [Ref.ID 99440]
8. Cita con resumen
Glyn-Jones S, Palmer AJR, Agricola R, Price AJ, Vincent TL, Weinans H, Carr AJ. Osteoarthritis. Lancet 2015;386:376-87. [Ref.ID 99368]
9.Tiene citas relacionadas Cita con resumen
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015;386:3 de octubre. [Ref.ID 99277]
10. Cita con resumen
Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick M. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med 2015;175:913-21. [Ref.ID 99183]
11. Cita con resumen
Anónimo. Diphosphonates: pseudo-gouttes. Prescrire 2014;34:833. [Ref.ID 98466]
12.Tiene citas relacionadas
Bischoff-Ferrari HA, Meyer O. Comparative effectiveness of pharmacologic treatments to prevent fractures: is this all we need to know?. Ann Intern Med 2014;161:711-23. [Ref.ID 98329]
13.Tiene citas relacionadas Cita con resumen
Crandall CJ, Newberry SJ, Diamant A, Lim Y-W, Gellad WF, Booth MJ, Motala A, Shekelle PG. Comparative effectiveness of pharmacologic treatments to prevent fractures: and updated systematic review. Ann Intern Med 2014;161:711-23. [Ref.ID 98328]
14. Cita con resumen
Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett-Connor E, Black DM. Effect of bisphosphonate use on risk of postmenopausal breast cancer. Results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med 2014;174:1550-7. [Ref.ID 97886]
15. Cita con resumen
Grados D, Martínez-Morillo M, Holgado S, Erra A. Bisfosfonatos intravenosos en la enfermedad ósea de Paget: mayor riesgo de efectos secundarios. Med Clin (Barc) 2014;142:469-70. [Ref.ID 97553]
16. Cita con resumen
Freemantle N, Cooper C, Díez-Pérez A, Gitlin M, Radcliffe H, Shepherd S, Roux C. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 2013;24:209-17. [Ref.ID 94651]
18. Cita con resumen
Boonen S, Reginster J-Y, Kaufman J-M, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012;367:1714-23. [Ref.ID 93959]
19.
Poole KE, Compston JE. Bisphosphonates in the treatment of osteoporosis. BMJ 2012;345:44-7. [Ref.ID 93569]
20.Tiene citas relacionadas Cita con resumen
Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis - For whom and for how long?. N Engl J Med 2012;366:2051-3. [Ref.ID 93039]
Seleccionar todas
 
 1 a 20 de 135 siguiente >>